Primary retroperitoneal lymph node dissection in stage II testicular seminoma: a systematic review.
germ cell cancer
metastatic
retroperitoneal surgery
seminoma
testicular
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
24 Oct 2024
24 Oct 2024
Historique:
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
24
10
2024
Statut:
aheadofprint
Résumé
To conduct a systematic review of the current literature to determine the current role of primary retroperitoneal lymph node dissection (RPLND) in stage II testicular seminoma and its associated oncological, functional and peri-operative outcomes. A comprehensive literature search was conducted in Medline, Embase, and Scopus for publications from inception until November 2023. The systematic review was registered on PROSPERO (ID CRD42023449781), was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and utilised the Methodological Index for Non-Randomised Studies (MINORS) tool. Six studies involving 385 patients were analysed, with 48.5% clinical stage IIA and 51.5% stage IIB seminomas. The patients' mean (range) age was 37 (20-64) years. The median operation time was 187 min, median estimated blood loss was 150 mL and median length of hospital stay was 4 days. In all, 6.1% of patients developed complications that were greater or equal to Clavien-Dindo grade 3. Only four studies reported on anejaculation rate (median: 4.9%). Only one study had long-term data, demonstrating a 92% 5-year overall survival for stage IIA/B disease treated with RPLND. The remaining five studies had a median follow-up of between 18.5 and 37 months and reported a mean recurrence rate of 15.6%. Most recurrences (78%) were not within the field of RPLND. Recurrence was associated with higher clinical and pathological lymph node stage, and metachronous or delayed development of retroperitoneal lymphadenopathy (initially stage I disease, as opposed to de novo stage IIA/B disease). Primary RPLND, performed by experienced surgeons, has good peri-operative outcomes. Recurrence is more common than with standard treatment, but long-term survival and functional data are limited, although promising.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 BJU International.
Références
Gilligan T, Lin DW, Aggarwal R et al. Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019; 17: 1529–1554
Gurney JK, Florio AA, Znaor A et al. International trends in the incidence of testicular cancer: lessons from 35 years and 41 countries. Eur Urol 2019; 76: 615–623
Park JS, Kim J, Elghiaty A, Ham WS. Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore) 2018; 97: e12390
Brierley JD, Rous B, Ev E, Asamura H. TNM Atlas: Illustrated Guide to the TNM Classification of Malignant Tumours. Hoboken: Wiley‐Blackwell, 2021
Patrikidou A, Cazzaniga W, Berney D et al. European Association of Urology guidelines on testicular cancer: 2023 update. Eur Urol 2023; 84: 289–301
Giannatempo P, Greco T, Mariani L et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta‐analysis of patient outcomes. Ann Oncol 2015; 26: 657–668
Haugnes HS, Bosl GJ, Boer H et al. Long‐term and late effects of germ cell testicular cancer treatment and implications for follow‐up. J Clin Oncol 2012; 30: 3752–3763
Warszawski N, Schmücking M. Relapses in early‐stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy. Scand J Urol Nephrol 1997; 31: 355–359
Garg H, Mansour AM, Psutka SP et al. Robot‐assisted retroperitoneal lymph node dissection: a systematic review of perioperative outcomes. BJU Int 2023; 132: 9–30
Ge S, Gan L, Meng C et al. Comparison of the perioperative outcomes of laparoscopic and open retroperitoneal lymph node dissection for low‐stage (stage I/II) testicular germ cell tumors: a systematic review and meta‐analysis. Int J Surg 2023; 109: 995–1005
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non‐randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 2003; 73: 712–716
Tabakin AL, Shinder BM, Kim S et al. Retroperitoneal lymph node dissection as primary treatment for men with testicular seminoma: utilization and survival analysis using the National Cancer Data Base, 2004‐2014. Clin Genitourin Cancer 2020; 18: e194–e201
Hiester A, Che Y, Lusch A et al. Phase 2 single‐arm trial of primary retroperitoneal lymph node dissection in patients with Seminomatous testicular germ cell tumors with clinical stage IIA/B (PRIMETEST). Eur Urol 2023; 84: 25–31
Daneshmand S, Cary C, Masterson T et al. Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy. J Clin Oncol 2023; 41: 3009–3018
Tachibana I, Alabd A, Tong Y et al. Primary retroperitoneal lymph node dissection for stage II seminoma: is surgery the new path forward? J Clin Oncol 2023; 41: 3930–3938
Heidenreich A, Paffenholz P, Hartmann F, Seelemeyer F, Pfister D. Retroperitoneal lymph node dissection in clinical stage IIA/B metastatic seminoma: results of the COlogne Trial of Retroperitoneal Lymphadenectomy in Metastatic Seminoma (COTRIMS). Eur Urol Oncol 2023; 7: 122–127
Matulewicz RS, Benfante N, Funt SA et al. Primary retroperitoneal lymph node dissection for seminoma metastatic to the retroperitoneum. J Urol 2023; 211: 80–89
McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 2003; 97: 63–70
Heinzelbecker J, Schmidt S, Lackner J et al. Therapy of clinical stage IIA and IIB seminoma: a systematic review. World J Urol 2022; 40: 2829–2841
Haugnes HS, Wethal T, Aass N et al. Cardiovascular risk factors and morbidity in long‐term survivors of testicular cancer: a 20‐year follow‐up study. J Clin Oncol 2010; 28: 4649–4657
Hellesnes R, Myklebust T, Fosså SD et al. Testicular cancer in the cisplatin era: causes of death and mortality rates in a population‐based cohort. J Clin Oncol 2021; 39: 3561–3573
Nicolai N, Tarabelloni N, Gasperoni F et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: safety and efficacy analyses at a high volume center. J Urol 2018; 199: 741–747
Hyams ES, Pierorazio P, Proteek O, Sroka M, Kavoussi LR, Allaf ME. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience. J Urol 2012; 187: 487–492
Classen J, Schmidberger H, Meisner C et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003; 21: 1101–1106
Chung PW, Gospodarowicz MK, Panzarella T et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 2004; 45: 754–759; discussion 9–60
Lisson CS, Manoj S, Wolf D et al. CT radiomics and clinical feature model to predict lymph node metastases in early‐stage testicular cancer. Onco 2023; 3: 65–80
Mano R, Di Natale R, Sheinfeld J. Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer. Urol Oncol 2019; 37: 209–218
Nappi L, Thi M, Lum A et al. Developing a highly specific biomarker for germ cell malignancies: plasma miR371 expression across the germ cell malignancy spectrum. J Clin Oncol 2019; 37: 3090–3098
Myklebust MP, Thor A, Rosenlund B et al. Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital‐droplet PCR in a prospective study. Sci Rep 2021; 11: 15582
Huddart RA, Reid AH, Mayer E, Sohaib SA, Nicol D. Clinical outcomes of minimally invasive retroperitoneal lymph node dissection and single dose carboplatin for clinical stage IIa seminoma. J Clin Oncol 2019; 37: 530
Tandstad T, Kjellman A, Almås B et al. Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA‐IIC ≤3cm: combined results of the SWENOTECA (Swedish Norwegian testicular cancer group) and Cologne. J Clin Oncol 2023; 41: 5008